FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2570222435> ?p ?o ?g. }

• W2570222435 endingPage "4265" @default.
• W2570222435 startingPage "4265" @default.
• W2570222435 abstract "Abstract Introduction: Given that the rate of cardiovascular (CV) morbidity increases with age and the median age of patients with multiple myeloma (MM) is 65, CV complications can occur during MM treatment. The proteasome inhibitors (PIs), bortezomib and carfilzomib, may play a role in the development of treatment-related cardiotoxicity as suggested by phase 2 clinical studies and a phase 3 trial (Stewart AK et al. N Engl J Med 2015;372:142-52). Reported treatment-related cardiotoxicity includes hypertension, congestive heart failure (CHF), myocardial infarction, and cardiac arrest. The objectives of this study are to define the incidence of cardiotoxicity in MM patients treated with bortezomib and carfilzomib and to evaluate whether the dose and pre-existing cardiac history affects that incidence. Study design and methods:Using the pharmacy database, we identified all MM patients treated at Memorial Sloan Kettering Cancer Center between 1/2010 to 10/2014 who were treated with bortezomib or carfilzomib in the second-line and relapsed refractory setting. Of note, all patients in the carfilzomib arm received prior bortezomib; thus, MM patients in the carfilzomib arm were more heavily pretreated and the two arms should be compared with caution. Data collected included: baseline demographics, baseline disease status, treatment given including dose and number of cycles, baseline cardiovascular comorbidities and medications, and pre- and post-treatment ejection fraction. Cardiotoxicity recorded was defined as grade 3 or more (requiring intervention) and included: hypertension, CHF, coronary artery disease, pulmonary hypertension, myocardial infarction, stroke, and/or arrhythmias. Descriptive statistics were used to analyze baseline demographics, including median and range for continuous variables and frequency and percentage for categorical variables. Fisher's exact test was used to assess the association between clinical and treatment characteristics and cardiotoxicity. Results: 157 patients were eligible for analysis with 47 in the bortezomib arm and 110 in the carfilzomib arm. The overall incidence of cardiotoxicity across both arms was 17% with an incidence of 9% (n = 4) and 20% (n = 22) in the bortezomib and carfilzomib arms, respectively. The most common events reported were arrhythmias (n = 3) with bortezomib and CHF (n = 12) with carfilzomib. The incidence of CHF and cardiomyopathy was 4% and 19% in the bortezomib and the more heavily pretreated carfilzomib arms, respectively. Baseline cardiac comorbidities were not found to increase the risk of cardiotoxicity while on treatment with carfilzomib (p = 0.815); due to small numbers, we were unable to assess this aspect in the bortezomib arm. Based on a categorization of carfilzomib dose (≤20 mg/m2, 27 mg/m2, or ≥36 mg/m2) starting on cycle 2, there was a significant association between the dose level received and cardiotoxicity (p=0.003); patients treated at dose level ≥36 mg/m2 were most likely to have a cardiac-related event while on therapy. Patients receiving the higher doses were treated on a clinical trial (Lendvai et al. Blood 2014;124:899-906), and they were among the most heavily pretreated. Management of cardiac events with carfilzomib was largely supportive with all patients requiring pharmacological intervention, 64% (n= 14) requiring hospital admission, and 73% (n = 16) requiring treatment delays. Conclusion: Grade 3 or more cardiotoxicity is a potential complication of treatment with PIs. However, there is no increased risk of CV deaths noted in our study. The results show a higher risk of cardiac toxicity in heavily pretreated MM patients receiving higher doses (≥36 mg/m2) of carfilzomib. The number of prior lines of therapy is a major factor when defining CV events in relation to a given therapy. Importantly, both carfilzomib and bortezomib are highly efficacious anti-myeloma drugs; CV risks should be assessed for individual patients and in relation to benefits. Disclosures Landgren: BMJ Publishing: Honoraria; Medscape: Honoraria; Bristol-Myers Squibb: Honoraria; Celgene: Honoraria; Onyx: Honoraria; International Myeloma Foundation: Research Funding; Onyx: Research Funding; BMJ Publishing: Consultancy; Medscape: Consultancy; Bristol-Myers Squibb: Consultancy; Celgene: Consultancy; Onyx: Consultancy." @default.
• W2570222435 created "2017-01-13" @default.
• W2570222435 creator A5018708120 @default.
• W2570222435 creator A5026740596 @default.
• W2570222435 creator A5044552886 @default.
• W2570222435 creator A5046310846 @default.
• W2570222435 creator A5082004555 @default.
• W2570222435 creator A5082707379 @default.
• W2570222435 creator A5082722205 @default.
• W2570222435 date "2015-12-03" @default.
• W2570222435 modified "2023-09-29" @default.
• W2570222435 title "Incidence and Management of Proteasome Inhibitor-Related Cardiotoxicity in Multiple Myeloma Patients at Memorial Sloan Kettering Cancer Center" @default.
• W2570222435 doi "https://doi.org/10.1182/blood.v126.23.4265.4265" @default.
• W2570222435 hasPublicationYear "2015" @default.
• W2570222435 type Work @default.
• W2570222435 sameAs 2570222435 @default.
• W2570222435 citedByCount "6" @default.
• W2570222435 countsByYear W25702224352016 @default.
• W2570222435 countsByYear W25702224352017 @default.
• W2570222435 countsByYear W25702224352018 @default.
• W2570222435 countsByYear W25702224352020 @default.
• W2570222435 countsByYear W25702224352021 @default.
• W2570222435 countsByYear W25702224352023 @default.
• W2570222435 crossrefType "journal-article" @default.
• W2570222435 hasAuthorship W2570222435A5018708120 @default.
• W2570222435 hasAuthorship W2570222435A5026740596 @default.
• W2570222435 hasAuthorship W2570222435A5044552886 @default.
• W2570222435 hasAuthorship W2570222435A5046310846 @default.
• W2570222435 hasAuthorship W2570222435A5082004555 @default.
• W2570222435 hasAuthorship W2570222435A5082707379 @default.
• W2570222435 hasAuthorship W2570222435A5082722205 @default.
• W2570222435 hasConcept C121608353 @default.
• W2570222435 hasConcept C126322002 @default.
• W2570222435 hasConcept C141071460 @default.
• W2570222435 hasConcept C143998085 @default.
• W2570222435 hasConcept C2776364478 @default.
• W2570222435 hasConcept C2776694085 @default.
• W2570222435 hasConcept C2777478702 @default.
• W2570222435 hasConcept C2778198053 @default.
• W2570222435 hasConcept C2778213512 @default.
• W2570222435 hasConcept C2778233292 @default.
• W2570222435 hasConcept C2778367456 @default.
• W2570222435 hasConcept C2780108899 @default.
• W2570222435 hasConcept C500558357 @default.
• W2570222435 hasConcept C71924100 @default.
• W2570222435 hasConcept C78085059 @default.
• W2570222435 hasConceptScore W2570222435C121608353 @default.
• W2570222435 hasConceptScore W2570222435C126322002 @default.
• W2570222435 hasConceptScore W2570222435C141071460 @default.
• W2570222435 hasConceptScore W2570222435C143998085 @default.
• W2570222435 hasConceptScore W2570222435C2776364478 @default.
• W2570222435 hasConceptScore W2570222435C2776694085 @default.
• W2570222435 hasConceptScore W2570222435C2777478702 @default.
• W2570222435 hasConceptScore W2570222435C2778198053 @default.
• W2570222435 hasConceptScore W2570222435C2778213512 @default.
• W2570222435 hasConceptScore W2570222435C2778233292 @default.
• W2570222435 hasConceptScore W2570222435C2778367456 @default.
• W2570222435 hasConceptScore W2570222435C2780108899 @default.
• W2570222435 hasConceptScore W2570222435C500558357 @default.
• W2570222435 hasConceptScore W2570222435C71924100 @default.
• W2570222435 hasConceptScore W2570222435C78085059 @default.
• W2570222435 hasIssue "23" @default.
• W2570222435 hasLocation W25702224351 @default.
• W2570222435 hasOpenAccess W2570222435 @default.
• W2570222435 hasPrimaryLocation W25702224351 @default.
• W2570222435 hasRelatedWork W155247308 @default.
• W2570222435 hasRelatedWork W1850271161 @default.
• W2570222435 hasRelatedWork W2063424779 @default.
• W2570222435 hasRelatedWork W2269989009 @default.
• W2570222435 hasRelatedWork W2339624602 @default.
• W2570222435 hasRelatedWork W2394791231 @default.
• W2570222435 hasRelatedWork W2521212135 @default.
• W2570222435 hasRelatedWork W2737046165 @default.
• W2570222435 hasRelatedWork W2783534173 @default.
• W2570222435 hasRelatedWork W3184357652 @default.
• W2570222435 hasVolume "126" @default.
• W2570222435 isParatext "false" @default.
• W2570222435 isRetracted "false" @default.
• W2570222435 magId "2570222435" @default.
• W2570222435 workType "article" @default.